Merck KGaA and BeiGene Collaborate in Co-Promotion Agreement
BeiGene and Merck KGaA, a top big pharma company have entered into a global licensing, co-development, co-promotion and commercialization agreement for BeiGene-283.
The compound is a second-generation BRAF inhibitor for the treatment of cancer.
BeiGene-283,which is currently in preclinical development, was discovered and developed in the People’s Republic of China by BeiGene.
It is expected to enter clinical development next year.
Under the terms of this development and co promotion collaboration, BeiGene will be responsible for the development and commercialization of BeiGene-283 in the People’s Republic of China and Merck KGaA will be responsible for the development and commercialization of BGB-283 for the rest of the world.
BeiGene will receive an undisclosed upfront payment and is eligible to receive further payments of up to US$ 233 million for the achievement of clinical development and potential commercial milestones in both the People’s Republic of China and rest of the world, as well as up to double digit royalties on net sales.
For further deal information visit Current Agreements (subscription required).
BeiGene is a Chinese oncology company focusing on discovering, developing and commercializing innovative, best-in-class, globally relevant oncology therapeutics. With a team of 150 scientists and staff, our pipeline is comprised of novel oral small molecules and monoclonal antibodies for cancer. BeiGene Ltd. is a Cayman Islands exempted company that is an investor in and collaborator with BeiGene (Beijing), Co. Ltd.
For more information, please visit the company’s website at www.beigene.com.